In recent years, a fascinating phenomenon has taken hold of society, challenging long-standing beliefs about the potential of psychotropics. Psychotropic-Assisted Therapy has emerged as a promising avenue to treat mental health and substance-abuse disorders.
A huge roster of Billionaires and Multi-Millionaires are supporting and investing in Psychotropic Therapy:
TOMS shoes founder Blake Mycoskie
A licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic treatment therapies.
LEARN MORE
Learn how Lucy Scientific Discovery's leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries are reimagining therapies for the Mental Health Crisis.
(NASDAQ: LSDI) is dedicated to the production of a variety of high-quality natural, synthetic, and biosynthetic products to meet the needs of the rapidly growing psychotropics-based medicines market.
(NASDAQ: LSDI) Taps Fortune 500 Veteran and Current Executive Chairman Richard Nanula as New CEO Nanula former CFO at Amgen and The Walt Disney Corporation to Bring Significant Strategic Focus and Leadership to Lucy Scientific Discovery. Read the news.
GH
Research PLC
(GHRS: NASDAQ)
$646MM Market Cap
Cybin
Inc.
(CYBN: NYSE American)
$55MM Market Cap
Seelos
Therapeutics Inc.
(SEEL: NASDAQ)
$144MM Market Cap
Mind
Medicine
(MNMD: NASDAQ)
$128MM Market Cap
Compass
Pathways PLC
(CMPS: NASDAQ)
$362MM Market Cap
Incannex
Healthcare Ltd
(IXHL: NASDAQ)
$111MM Market Cap
Atai Life
Sciences
(ATAI: NASDAQ)
$270MM Market Cap
Lucy Scientific Discovery Inc
(LSDI: NASDAQ)
$18MM Market Cap
Lucy completed the acquisition of Wesana Health Inc.'s SANA-013 assets, making a significant milestone in the field of mental health therapeutics. This acquisition strengthens Lucy's position.
According to the U.S. Department of Veterans Affairs, 11-20 out of every 100 veterans experience post-traumatic stress disorder — a number that is both overwhelming and, unfortunately, not always acknowledged to the degree that it should be.
The psychological effects of combat can be profound, and post-war mental illness among veterans encompasses a wide range of conditions including depression, anxiety, and substance abuse.
GETTY IMAGES
Previous studies by Johns Hopkins Medicine researchers showed that psychedelic treatment with psilocybin relieved major depressive disorder symptoms in adults for up to a month. Now, in a follow-up study of those participants, the researchers report that the substantial antidepressant effects of psilocybin-assisted therapy, given with supportive psychotherapy, may last at least a year for some patients.
(NASDAQ: LSDI) is dedicated to the production of a variety of high-quality natural, synthetic, and biosynthetic products to meet the needs of the rapidly growing psychotropics-based medicines market.
By leveraging various scalable production methods, Lucy Scientific Discovery is uniquely positioned to effectively support current and future market needs at competitive prices.
Lucy Scientific Discovery works directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth.
You and your loved ones are likely affected by someone with mental health or substance abuse issues. The impact of these diseases can cause substantial emotional stress, leaving you feeling overwhelmed.
Studies from some of the leading institutions in the world on psychotropics-based treatment have demonstrated significant and durable improvements in depression and anxiety. Isn’t it time the market rewards the leading companies in this space?
Without treatment, the consequences of mental illness for the individual and society are staggering. Untreated mental health conditions can result in unnecessary disability, unemployment, substance abuse, homelessness, inappropriate incarceration, and suicide, and poor quality of life.
“Pasithea’s most recent quarterly report indicates approximately $30,000,000 cash on hand. Given the significant market value discount to its net cash, Lucy believes its attractive offer will create immediate value from the cash portion with additional upside participation through Lucy’s stock as it executes its business plan.”
According to Future Market Insights, “The global Psychotropics Market is estimated to exhibit growth at a CAGR of around 6%-7% over the forecast period 2022-2023. Growing awareness regarding the severity of mental illnesses and increasing introduction of new psychological therapies safe and effective treatment of psychological disorders is expected to propel the demand for psychotropics in the global market.”
Psychotropics have emerged as a potential game changer in the field of mental health treatment. With their ability to target specific neurotransmitters and modulate brain activity, these medications have revolutionized the management of various psychiatric disorders.
Psychotropics have provided individuals with effective options for treating conditions such as depression, anxiety, mood disorder, and PTSD, among others. They have the potential to alleviate symptoms, restore balance, and improve overall quality of life.
By offering relief from debilitating symptoms and enabling individuals to function optimally, psychotropics have transformed the landscape of mental health care, providing hope and possibilities for countless individuals and their families.
Richard Nanula, Lucy’s CEO and Executive Chairman, is a highly experienced senior executive and former Executive Vice President and CFO at the Walt Disney Company, CEO of Broadband Sports, President and COO of Starwood Hotels, EVP of Finance and Strategy at Amgen, Principal at Colony Capital and is an esteemed graduate of Harvard Business School.
Dr. Assad J. Kazeminy, Lucy’s CSO, has 30+ years in biotechnology research and development and is an expert in the facilitation of qualified trials.
The dynamic and evolving psychotropic market presents several potential acquisition targets that could drive growth and expansion for pharmaceutical companies.
Companies specializing in the development of novel antidepressants oranxiolytics with unique mechanisms of action could be attractive targets, as they offer the potential for differentiated treatment options. Similarly, companies focused on developing innovative antipsychotic medications with improved efficacy and reduced side effects may garner interest. Additionally, acquisition targets may include companies involved in the development of digital therapeutics or telemedicine platforms that enhance the delivery of mental health care.
With the increasing demand for personalized medicine, companies specializing in precision psychiatry, utilizing genetic and biomarker data to tailor treatment, may also be attractive.
The psychotropic market presents a range of potential acquisition targets that align with the growing need for innovative and effective solutions in mental health treatment.
The market size for Psychotropics is in the BILLIONS.
Leading Global Research Institutions are continuing to dedicate vast research dollars to study the benefits of psychotropics in the treatment of depression, anxiety, PTSD and addiction.
The Company announced a share repurchase program in April of this year.
Management is pursuing a strategic acquisition of a cash-rich NASDAQ business, specializing in discovering new treatments for mental health disorders.
The Research and Development Pipeline is being led by Dr. Assad J. Kazeminy to develop and assess the company's pipeline of psychotropics to determine the potential for future growth.
The Psychotropic Market is in its infancy, with new therapies being introduced and accepted at a break-neck pace.
Clinical Data continues to emerge supporting the safety and efficacy of Psychotropics, which is increasing market acceptance.
The company boasts a highly effective management team with extensive experience in psychopharmacology, development, and commercialization, positioning them for success in the dynamic and evolving mental health market.
Highly experienced senior executive and former Executive Vice President and CFO at the Walt Disney Company, Mr. Nanula brings to bear a magnitude of leadership and strategy insights at the highest levels. Nanula’s various other executive roles include CEO of Broadband Sports, President and COO of Starwood Hotels, EVP of Finance and Strategy at Amgen, and Principal at Colony Capital.
In addition to Mr. Nanula’s executive leadership experience, he has also served in numerous director and advisory board positions throughout his professional tenure. Nanula is highly regarded as an investment advisor and is an esteemed graduate of Harvard Business School.
With a doctorate in pharmaceutical sciences, graduate studies in biochemistry, and a post-doctorate degree in pharmacology, Dr. Kazeminy has over 30 years of research and development experience in the biopharmaceutical industry, earning his place as a highly established authority of emerging biopharmaceutical advancement throughout the U.S. and Canada.
Having founded and served as CEO of Irvine Pharmaceutical Services Inc. and Avrio Biopharmaceutical LLC, Dr. Kazminy has served in a variety of positions over his impressive career, to include membership in the US Pharmacopeia Console of Experts and the UC Irvine Chief Executive Roundtable, to name a few.
Dr. Kazeminy is an expert in the facilitation of qualified trials and brings with him an undeniable track record of implementing best practices to ensure the validity and credibility of research outcomes. Dr. Kazeminy intends to leverage his vast network to enable the Lucy team to best support the psychotropic therapies industry as it continues to mature.
Highly experienced senior executive and former Executive Vice President and CFO at the Walt Disney Company, Mr. Nanula brings to bear a magnitude of leadership and strategy insights at the highest levels. Nanula’s various other executive roles include CEO of Broadband Sports, President and COO of Starwood Hotels, EVP of Finance and Strategy at Amgen, and Principal at Colony Capital.
In addition to Mr. Nanula’s executive leadership experience, he has also served in numerous director and advisory board positions throughout his professional tenure. Nanula is highly regarded as an investment advisor and is an esteemed graduate of Harvard Business School.
A leading corporate securities lawyer based in Calgary, Alberta, Canada for more than 25 years, Mr. Reeves leverages a wealth of experience in private and public debt and equity offerings, corporate acquisitions, structuring, and debt financing.
In addition to serving as Partner at TingleMerrett LLP since 2003, Reeves also acts as director of Radiko Holdings, Inc. (2017), Tree of Knowledge International Corp. (2018), Navion Capital Corp. (2018), CBD Global Sciences Inc. (2019), and Starrex International Ltd. (2019).
A globally renowned expert in dataprotection and privacy, technology policy, and legislative reform, Ms. Kaiserhas worked on the leading edge of human-technology interface and education.Utilizing this foundational core of expertise, she has worked with variousinterdisciplinary teams to design, develop, and refine new technologies andconsumer products.
Kaiser is the Co-Founder, President, and Director of the Own Your Data Foundation, and Co-Founder of the Digital Asset Trade Association (DATA) Technology for legal advocacy where she does legislative drafting and lobbying on privacy and blockchain initiatives.
With more than 40 years of experience in early-stage start-up, exploration financing, corporate governance, regulatory affairs, and project management, Mr. Susin represents a litany of strategy knowledge.
Susin is the Founder of Navion Capital Inc., a CPC listed on the TSX where he currently serves on the board of directors. Additionally, he has served on the boards of numerous publicly traded companies including Tock Tech Lithium Inc. and RDS Software, Inc.
As the chair of the Department of Psychiatry and Behavioral Sciences at the University of Texas, Austin, Dell Medical School, Dr. Nemeroff is a highly respected and well-published authority on international mental health research.
Dr. Nemeroff has received multipleawards for research and education in his field and has published more than1,100 research reports and reviews. Additionally, Nemeroff has served innumerous esteemed board and council positions, including president of theAmerican College of Psychiatrists and the American College ofNeuropsychopharmacology.
A leader in corporate finance and strategy development, Mr. Abramowitz has led numerous successful ventures and high-value exits in his 35+ years of business experience. He has successfully helmed more than 20 enterprises driving change through strategic repositioning and organizational transformation.
Mr. Abramowitz founded a baby supply manufacturing company, Pur, leading it to numerous successes until it was acquired by Hasbro, Inc. Additionally, Abramowitz has served in various C-suite capacities, driving continuity and growth for Neah Power Systems, DAK Industries, Inn Keepers of America, and Experience Music Project.
Securities Counsel
Lucosky Brookman LLP
101 Wood Avenue South
Woodbridge, New Jersey 08830
(212) 417-8160
www.luckbro.com
Accounting/Auditing Firm
Marcum LLP
730 Third
Avenue
11th Floor
New York, NY 10017
212-485-5500
www.marcumllp.com
Transfer Agent
Stock Transfer, LLC
18 Lafayette
Pl
Woodmere, NY 11598
212-828-8436
www.vstocktransfer.com
THIS WEBSITE CONTAINS FORWARD LOOKING STATEMENTS
All statements in this website and attached documents, including videos, are not historical facts and are forward-looking statements which involve risks and uncertainties; actual results may differ from the forward-looking statements. Sentences or phrases which use such words as “projected”, “expect”, “believe”, “anticipates”, “hopeful”, “looking”, “market penetration”, “goal”, “target”, “hopeful”, “should”, “working to”, “working toward”,” pro-forma”, “developing”, “develop”, “research, “investing” and others indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
These forward-looking statements and projections should not be relied upon, but are provided only to show a theoretical outcome. Actual results may be materially different. We cannot and do not warrant the accuracy, completeness or timeliness of the information contained therein. We caution you that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.
For further information, please contact us at:
Email: [email protected]
Website for Informational Purposes Only
Information, opinions, or recommendations contained in this website are submitted solely for informational purposes. The information used in statements of fact made has been obtained from sources considered reliable, but we neither guarantee nor represent their completeness or accuracy. Such information and the opinions expressed are subject to change without notice. The views expressed in this website accurately reflect Lucy Scientific Discovery, Inc.’s subjective views about any or all of the subjects discussed on this website.
This website is not intended as an offering or a solicitation of any offer to buy or sell any securities mentioned or discussed.
Any opinions expressed herein reflect the opinion of Lucy Scientific Discovery, Inc., and are subject to change without notice.
Investors should consider the suitability of any particular investment based on their ability to accept certain levels of risk, and should not rely solely on this website for information pertaining to Lucy Scientific Discovery, Inc. The material in this website is intended for general information only and any recommendations contained herein do not consider the specific objectives, financial situation, or particular needs of any particular person. Information contained on this website is not meant as, and should not be considered as, a recommendation. An investor should consult his investment representative regarding the suitability of any investment in the company and take into account any specific investment objectives, financial situation, or particular needs before he or she makes a commitment to purchase the shares of this or any other company’s stock. No part of this document may be reproduced in any manner without the written permission of Lucy Scientific Discovery, Inc. Disclosure Concerning Lucy Scientific Discovery, Inc.
LUCY SCIENTIFIC DISCOVERY, Inc. trades on the Nasdaq Capital Market and all of its annual and quarterly financial reports are filed with the SEC and can be found on EDGAR, or on www.sec.gov.
Links From www.LucyScientific.com to Third Party Websites
This website may be linked to other sites on the World Wide Web that are not under the control of or maintained by Lucy Scientific Discovery, Inc. Such links do not constitute an endorsement by Lucy Scientific Discovery, Inc. of any such sites. You acknowledge that Lucy Scientific Discovery, Inc. is providing these links to you only as a convenience, and you agree that Lucy Scientific Discovery, Inc. is not responsible for the content or links displayed on such sites to which you may be linked.
Links found on this website may direct you to the other websites and information contained on those websites. Clicking on such a link will direct you away from our website. Lucy Scientific Discovery, Inc. does not control the content or information contained on any such website. The information on such websites has not been verified by Lucy Scientific Discovery, Inc. The viewer should use caution and prudence when viewing such information.
Your use of such third-party sites is at your own risk. Those Sites may include inaccuracies or errors that may affect the quality of the materials on the Site. The materials have not been independently verified or authenticated in whole or in part by Lucy Scientific Discovery, Inc. Lucy Scientific Discovery, Inc. does not warrant the accuracy or timeliness of the materials. Lucy Scientific Discovery, Inc. has no liability for any errors or omissions in the materials provided on third party sites.
Disclaimer of Warranties Your use of this Site is at your own risk. This Site may include inaccuracies or errors that may affect the quality of the materials on the Site. Lucy Scientific Discovery does not guarantee the accuracy or timeliness of the materials.
Lucy Scientific Discovery has no liability for any errors or omissions in the materials. THIS SITE IS PROVIDED TO YOU ON AN “AS IS” AND “WHERE-IS” BASIS, WITHOUT ANY WARRANTY. LUCY SCIENTIFIC DISCOVERY, FOR ITSELF PROVIDING MATERIALS, SERVICES, OR CONTENT TO THIS WEBSITE, MAKE NO REPRESENTATIONS OR WARRANTIES IN CONNECTION WITH THE SITE INCLUDING BUT NOT LIMITED TO THE QUALITY, SUITABILITY, TRUTH, ACCURACY OR COMPLETENESS OF ANY MATERIAL, INFORMATION, PRODUCT, OR SERVICE CONTAINED ON THE SITE. ALL CONDITIONS, REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THIRD-PARTY RIGHTS, ARE HEREBY DISCLAIMED. LUCY SCIENTIFIC HAS PAID TOTOALIGENT, INC. ONE HUNDRED AND FIFTY THOUSAND DOLLARS FOR DIGITAL TRAFFIC TO THIS INFORMATION PAGE. LUCY SCIENTIFIC DISCOVERY WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY DAMAGES OF ANY KIND, INCLUDING BUT NOT LIMITED TO, DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, ARISING FROM OR CONNECTED WITH THE SITE, INCLUDING BUT NOT LIMITED TO, YOUR USE OF THIS SITE OR YOUR INABILITY TO USE THE SITE, EVEN IF LUCY SCIENTIFIC DISCOVERY HAS PREVIOUSLY BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
LUCY SCIENTIFIC DISCOVERY controls and operates this Site from its headquarters in British Columbia, Canada and makes no representation that the materials are appropriate or will be available for use in other locations. Unless otherwise explicitly stated, all marketing or promotional materials found on this Site are solely directed to individuals, companies or other entities located in the United States. If you use this Site from outside the United States of America, you are entirely responsible for compliance with applicable local laws, including but not limited to the export and import regulations.
For more company information go to LucyScientific.com